Imricor Medical Systems (ASX:IMR) Net Income From Continuing Operations: A$-54.10 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:IMR Imricor Medical Systems Inc ASX:IMR
41 GF Score
Price A$1.90
GF Value A$0.16
Valuation Significantly Overvalued
! 11 Warning Signs
View Full Analysis

What is Imricor Medical Systems Net Income From Continuing Operations?

Imricor Medical Systems ASX:IMR -1.56% 41 Net Income From Continuing Operations is A$-54.10 Mil as of Jun. 2026. GuruFocus rates ASX:IMR with a GF Score™ of 41/100 and a GF Value™ of A$0.16 (Significantly Overvalued). The stock has 11 warning signs investors should review.

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Imricor Medical Systems's net income from continuing operations for the six months ended in Jun. 2026 was A$-35.77 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2026 was A$-54.10 Mil.

Imricor Medical Systems Net Income From Continuing Operations Historical Data

* Premium members only.

The historical data trend for Imricor Medical Systems's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imricor Medical Systems Net Income From Continuing Operations Chart

Imricor Medical Systems Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income From Continuing Operations
Get a 7-Day Free Trial -27.59 -25.72 -33.80 -46.89 -38.11

Imricor Medical Systems Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.33 -36.06 -20.19 -18.33 -35.77
ASX:IMR
41GF Score
Imricor Medical Systems Inc ASX:IMR
Net Income From Continuing Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Imricor Medical Systems Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-54.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income From Continuing Operations of A$-54.10 Mil mean?
Imricor Medical Systems (ASX:IMR) has a Net Income From Continuing Operations of A$-54.10 Mil as of Jun. 2026. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Imricor Medical Systems and its competitors.
Is Imricor Medical Systems' Net Income From Continuing Operations too high?
Imricor Medical Systems' current Net Income From Continuing Operations is A$-54.10 Mil. Overall, Imricor Medical Systems has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Imricor Medical Systems' Net Income From Continuing Operations compare to ABT and SYK?
Imricor Medical Systems' Net Income From Continuing Operations of A$-54.10 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income From Continuing Operations for a Medical Devices & Instruments company?
A good Net Income From Continuing Operations depends on the Medical Devices & Instruments industry context. However, Net Income From Continuing Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income From Continuing Operations mean?
A high Net Income From Continuing Operations can signal that a stock is expensive relative to its fundamentals. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Imricor Medical Systems and its competitors. Imricor Medical Systems's current Net Income From Continuing Operations is A$-54.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imricor Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, Imricor Medical Systems (ASX:IMR) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.16, compared to a current price of A$1.90 — trading 1084.4% above its estimated fair value. The current Net Income From Continuing Operations is A$-54.10 Mil. Imricor Medical Systems' overall GF Score™ is 41/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income From Continuing Operations calculated?
Net Income From Continuing Operations is calculated from a company's financial statements. For Imricor Medical Systems (ASX:IMR), the current Net Income From Continuing Operations is A$-54.10 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Imricor Medical Systems (ASX:IMR) Overvalued in 2026?

Based on GuruFocus' analysis, Imricor Medical Systems stock appears to be overvalued. The current stock price of A$1.90 is trading 1084.4% above its estimated GF Value™ of A$0.16. GuruFocus considers Imricor Medical Systems to be Significantly Overvalued.

Key valuation signals for ASX:IMR:

  • Net Income From Continuing Operations: A$-54.10 Mil
  • GF Value™: A$0.16 vs. price of A$1.90 (1084.4% above fair value)
  • GF Score™: 41/100 with 11 warning signs

No single metric tells the full story. See the ASX:IMR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Imricor Medical Systems Business Description

Address 400 Gateway Boulevard, Burnsville, MN, USA, 55337
Imricor Medical Systems Inc is a medical device company that develops MRI-guided technology to address issues with traditional X-ray ablation procedures. Its principal business activities are designing, manufacturing, and selling MRI-compatible products for cardiac catheter ablation procedures to treat arrhythmias. The company's products include the Advantage-MR EP Recorder/Stimulator, Vision-MR Ablation Catheter, and Vision-MR Dispersive Electrode. Geographically, the company generates maximum revenue from Europe.
41GF Score

Get the complete analysis for ASX:IMR

Net Income From Continuing Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.90
Price
A$0.16
GF Value